# Clinical Trials Data ALK - Document 31

# The Oncopanel Pilot (TOP) Study

## Clinical Trial: https://clinicaltrials.gov/study/NCT02171286

"eligibilityCriteria": "Patients with archival tumor tissue and a known history of invasive malignancies are eligible if they meet one or more of the following criteria:\n\n\* Advanced colorectal cancer and eligible for standard KRAS testing,\n\* Advanced non-small cell lung cancer and eligible for standard EGFR testing,\n\* Advanced melanoma and eligible for standard BRAF testing,\n\* Gastrointestinal stromal tumors (GISTs) eligible for standard c-KIT and PDGFRA testing,\n\* Being considered for potential eligibility in clinical trial.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with advanced colorectal cancer, non-small cell lung cancer and melanoma and candidates for clinical trials.",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with an ALK gene mutation would not specifically qualify under the conditions listed. The criteria specify particular mutations and conditions for which types of cancer qualify:  
  
- Advanced colorectal cancer with KRAS testing eligibility  
- Advanced non-small cell lung cancer with EGFR testing eligibility  
- Advanced melanoma with BRAF testing eligibility  
- Gastrointestinal stromal tumors (GISTs) with c-KIT and PDGFRA testing eligibility  
  
These criteria do not mention ALK gene mutations or related testing. If the patient has advanced non-small cell lung cancer and is eligible for other standard testing, they might still be considered for "potential eligibility in clinical trial," but this is not specific to an ALK mutation. Further inquiry with the trial coordinators or specific trial documentation would be necessary for clarification on whether an ALK mutation might be considered outside the criteria listed or potentially under the "being considered for potential eligibility in clinical trial" clause.